Hanger Downgraded to Sell - Analyst Blog
14 May 2014 - 6:24AM
Zacks
On May 7, 2014, Zacks Investment Research downgraded
Hanger Inc. (HGR) by a notch to a Zacks Rank #4
(Sell).
Why the Downgrade?
For 2014, three estimates moved south in the last one month, with
no upward revision in the same time frame, causing the Zacks
Consensus Estimate to drop 5.6% to $2.04 per share. For 2015, three
estimates were down in the past 7 days, leading to a 3.6% fall in
Zacks Consensus Estimate to $2.39.
Hanger clocked negative earnings surprises in 2 of the last 4
quarters, with an average miss of 3.9%.
On May 5, 2014, Hanger reported its 2014-first-quarter results,
which lagged estimates at both fronts. Following the earnings
release, shares of Hanger dropped 10.8%.
Adjusted earnings per share of 19 cents reflected a year-over-year
drop of 29.6% and lagged the Zacks Consensus Estimate of 23 cents.
Revenues in the quarter inched up 2.7% to $235.6 million but fell
short of the Zacks Consensus Estimate of $242 million.
Revenue growth was driven by improvement in the Patient Care
segment, partially offset by a decline in the Products &
Services segment revenues due to adverse weather conditions in the
U.S. throughout the first quarter.
Hanger’s adjusted operating margin fell 300 basis points to 7.1% in
the quarter owing to lower-than-expected sales and increased
costs.
Furthermore, Hanger reported $10.0 million in cash outflow from
operations led by lower operating income and increased working
capital requirements.
Reflecting the lackluster first-quarter results, Hanger lowered its
2014 adjusted earnings per share guidance to a range of $2.01 to
$2.11 from the prior range of $2.10 to $2.20. The Zacks Consensus
Estimate of $2.04 lies within the guided range.
Hanger also slashed its 2014 revenue guidance to $1,100–$1,120
million from the previous band of $1,110–$1,130 million. The
current Zacks Consensus Estimate of $1,101 million lies within the
guided range.
Owing to the uncertain reimbursement environment, sequestration and
RAC audits, Hanger is likely to face challenges that will
pressurize its top line going forward.
Other Stocks to Consider
Some better-ranked medical product stocks include Cardica
Inc. (CRDC), Enzymotec Ltd. (ENZY) and
Mead Johnson Nutrition Co. (MJN). All these stocks
carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days. Click
to get this free report
CARDICA INC (CRDC): Free Stock Analysis Report
ENZYMOTEC LTD (ENZY): Free Stock Analysis Report
HANGER ORTHOPED (HGR): Free Stock Analysis Report
MEAD JOHNSON NU (MJN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Sep 2024 to Oct 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Enzymotec Ltd. - Ordinary Shares (delisted) (NASDAQ): 0 recent articles
More ENZYMOTEC LTD. News Articles